| ALBIO Stock | | | EUR 2.88 0.06 2.13% |
Chairman
Mr. Larry Abensur was a Director of Biosynex SA since February 11, 2005. He holds an Engineering degree from Ecole Nationale Superieure de Chime de Paris as well as a MBA degree from INSEAD. After nine years experience in pharmaceutical marketing working as human biosynthetic insulin product manager at Eli Lilly, he then joined Upjohn France as Marketing Manager. He subsequently served as Chief Executive Officer of PBS Orgenics, an in vitro diagnostic company, for six years until the merger with Self Care and the listing on the Nasdaq stock exchange. In 1993 and 1994, Mr. Abensur cofounded All Diag and Dectra Pharm. In 2005, he took part in the creation of Biosynex SA, in which he served as a CoManager until October 2010. Mr. Abensur currently holds various mandates, including President of SAS Dectra Pharm, SAS Laboratoire SBH and GIE Lab OTC, as well as Manager of SARL Ala Financiere, among others. since 2005.
| Tenure | 19 years |
| Phone | 33 3 88 78 78 87 |
| Web | https://www.biosynex.com |
Biosynex Management Efficiency
The company has return on total asset
(ROA) of
0.4451 % which means that it generated a profit of $0.4451 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.8886 %, meaning that it generated $0.8886 on every $100 dollars invested by stockholders. Biosynex's management efficiency ratios could be used to measure how well Biosynex manages its routine affairs as well as how well it operates its assets and liabilities.
Biosynex has accumulated 29.16
M in total debt with debt to equity ratio
(D/E) of 17.7, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biosynex has a current ratio of 1.9, which is within standard range for the sector. Debt can assist Biosynex until it has trouble settling it off, either with new capital or with free cash flow. So, Biosynex's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biosynex sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biosynex to invest in growth at high rates of return. When we think about Biosynex's use of debt, we should always consider it together with cash and equity.
Similar Executives
Biosynex SA designs, manufactures, and distributes rapid diagnostic tests in France and internationally. The company was founded in 1993 and is based in Illkirch-Graffenstaden, France. BIOSYNEX is traded on Paris Stock Exchange in France. Biosynex (ALBIO) is traded on Euronext Paris in France and employs 320 people.
Management Performance
Biosynex Management Team
Elected by the shareholders, the Biosynex's board of directors comprises two types of representatives: Biosynex inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biosynex. The board's role is to monitor Biosynex's management team and ensure that shareholders' interests are well served. Biosynex's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biosynex's outside directors are responsible for providing unbiased perspectives on the board's policies.
Biosynex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biosynex a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Additional Tools for Biosynex Stock Analysis
When running Biosynex's price analysis, check to
measure Biosynex's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosynex is operating at the current time. Most of Biosynex's value examination focuses on studying past and present price action to
predict the probability of Biosynex's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosynex's price. Additionally, you may evaluate how the addition of Biosynex to your portfolios can decrease your overall portfolio volatility.